Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
Repligen (RGEN) Delivers Record Q3 Revenue Up +10.9% and Raises Full-Year Guidance

Repligen (RGEN) Delivers Record Q3 Revenue Up +10.9% and Raises Full-Year Guidance

Key Takeaways

  • Repligen posted record third-quarter revenue of $209.3 million, up 10.9% year over year and slightly ahead of the roughly $207 million consensus estimate.
  • Adjusted earnings per share (EPS) of $0.53 beat analyst expectations of $0.46, while organic revenue growth reached 12.5%.
  • On a GAAP basis, the company reported a net loss of $38.4 million, or $0.68 per share, driven by a $41 million intangible asset impairment charge.
  • Management raised full-year 2026 guidance, with revenue now expected between $844 million and $852 million and adjusted EPS near $2.07 at the midpoint.
  • Franchise performance was mixed: chromatography grew more than 50%, proteins more than 40%, and analytics 20%, while filtration declined 11%.

Earnings Context and Why It Matters

Repligen is a leading supplier of bioprocessing technologies used to manufacture biological drugs, serving biopharmaceutical developers and contract development and manufacturing organizations (CDMOs). Its results are closely watched as a barometer of demand across the broader bioprocessing supply chain, which has been recovering from a post-pandemic inventory correction. A record revenue quarter and rising organic growth suggest that customer demand for consumables and services is firming, even as capital equipment purchases remain uneven. The quarter also carried an unusual GAAP wrinkle: a large non-cash intangible impairment charge tied to an older intellectual property agreement. For investors, the report highlights both improving end-market momentum and the accounting noise that can obscure underlying operating progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

For the third quarter ended September 30, 2026, Repligen reported total revenue of $209.31 million, a 10.9% increase from $188.81 million a year earlier and modestly above the consensus estimate of about $206.75 million. Organic growth, which excludes acquisitions, divestitures, and foreign exchange, was 12.5%.

Adjusted (non-GAAP) diluted EPS came in at $0.53, topping the FactSet consensus of $0.46 by roughly 14.6%. Adjusted operating income rose 24% year over year to $33 million, and adjusted operating margin expanded 170 basis points to 15.9%. Adjusted EBITDA reached approximately $43.8 million, a 20.9% margin.

On a GAAP basis, results were weighed down by a $41 million non-cash intangible asset impairment charge related to an intellectual property license agreement. This contributed to a reported net loss of $38.4 million, or $0.68 per diluted share, versus net income of $14.9 million, or $0.26 per share, in the prior-year quarter.

Management also raised its full-year 2026 outlook, reflecting strength across the portfolio and the October 6 acquisition of BioLife. Revenue guidance was increased to a range of $844 million to $852 million, with BioLife expected to contribute roughly $24 million in the fourth quarter.

Market Reaction and Investor Sentiment

Investor response to the results appeared mixed. The company delivered a clear earnings beat on adjusted metrics and raised full-year guidance, which typically supports positive sentiment. However, the headline GAAP loss, driven by the sizable intangible impairment, introduced a layer of caution. Sentiment heading into the print had been constructive as bioprocessing demand gradually improved, and management's commentary about record capital equipment orders and strong China growth reinforced the narrative of a recovering end market. At the same time, the filtration segment's 11% decline, partly reflecting an anticipated headwind plus equipment delivery timing, remained a point of focus. Overall, the market's interpretation centered on the durability of consumables demand and the pace of capital equipment recovery rather than the one-time accounting charge.

Forward Outlook and Key Factors to Monitor

Following this report, investors are likely to focus on several forward-looking themes. First, guidance execution will matter: management now expects full-year revenue between $844 million and $852 million, with organic growth of 12% to 13%. The BioLife integration and its expected fourth-quarter contribution will be an early test of the company's cell therapy expansion strategy.

Second, the capital equipment cycle deserves close attention. Although equipment revenue declined in the quarter as deliveries shifted into 2027, orders grew by mid-teens and reached their highest quarterly level in five years. How quickly that backlog converts into recognized revenue will shape near-term growth visibility.

Third, margin trends remain important. Management indicated that the third quarter was expected to mark the low point for gross margin in 2026, and investors will watch whether product mix, pricing, and volume leverage support continued adjusted operating margin expansion.

Finally, regional dynamics, particularly China's greater than 40% growth, and the progression of consumables and services demand will be key indicators of underlying bioprocessing health as the industry continues its gradual recovery. From what I see, tracking these elements with tools like Tickeron’s AI Daily Buy/Sell Signals can help stay on top of shifting conditions.

Using Tickeron AI Tools in My Research

In my regular analysis of companies like RGEN, I rely on Tickeron’s AI Trading Bots to simulate strategies and test scenarios across different market conditions. This approach gives me a clearer view of potential outcomes without replacing my own judgment, and it has become a practical part of evaluating earnings reports and guidance updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RGEN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RGEN in downward trend: 10-day moving average broke below 50-day moving average on November 11, 2026

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 70 cases where RGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry PharmaceuticalsOther

Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
2000
Web
https://www.repligen.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.